Hosted by IDTechEx
Global Biotechnology Insights
Posted on March 5, 2020 by  & 

First Ever CRISPR Gene Editing Within the Human Body

The gene-editing tool CRISPR has been used to address a blindness-causing gene mutation at Oregon Health & Science University for a clinical trial sponsored by Allergan plc and Editas Medicine.
 
The procedure marks the first time CRISPR has been used to edit human genes within the body, which is also called in vivo gene editing. Previous gene-editing methods have involved editing genetic material after it was removed from the body. The trial's gene editing approach is designed to be permanent, but not passed onto the offspring of those who receive it. More information is in today's announcement from the trial sponsors. For more information see the IDTechEx report on Synthetic Biology 2018.
 
Clinicians with OHSU's Casey Eye Institute performed the procedure for the BRILLIANCE clinical trial, which seeks to repair mutations in the CEP290 gene that cause a rare form of inherited blindness called Leber congenital amaurosis type 10; also known as LCA10 and CEP290-related retinal dystrophy. Most people with the mutation are either born blind or become blind within the first decade of their life.
 
"Being able to edit genes inside the human body is incredibly profound," said Mark Pennesi, M.D., Ph.D., who leads OHSU's involvement in the trial and is the Kenneth C. Swan associate professor of ophthalmology in the OHSU School of Medicine; and, chief of the OHSU Casey Eye Institute's Paul H. Casey Ophthalmic Genetics Division. "Beyond potentially offering treatment for a previously untreatable form of blindness, in vivo gene editing could also enable treatments for a much wider range of diseases."
 
 
Source: Oregon Health and Science University
Top image: Pixabay
Learn more at the next leading event on the topic: Healthcare Sensor Innovations USA 2020 External Link on 18 - 19 Nov 2020 at Santa Clara Convention Center, CA, USA hosted by IDTechEx.
More IDTechEx Journals